PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells

The introduction of second-generation tyrosine kinase inhibitors (TKIs) targeting the protein-tyrosine kinase (PTK) BCR-ABL1 has improved treatment response in chronic myeloid leukemia (CML). However, in some patients response still remains suboptimal. Protein-tyrosine phosphatases (PTPs) are natura...

Descripción completa

Detalles Bibliográficos
Autores principales: Drube, Julia, Ernst, Thomas, Pfirrmann, Markus, Albert, Benadict Vincent, Drube, Sebastian, Reich, Daniela, Kresinsky, Anne, Halfter, Kathrin, Sorio, Claudio, Fabisch, Christian, Hochhaus, Andreas, Böhmer, Frank-D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823647/
https://www.ncbi.nlm.nih.gov/pubmed/29507701
http://dx.doi.org/10.18632/oncotarget.24253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823647/
https://www.ncbi.nlm.nih.gov/pubmed/29507701
http://dx.doi.org/10.18632/oncotarget.24253

Ejemplares similares